Nasdaq

Natera Submits First PMA Module to the FDA for Signatera™

Lays groundwork for multiple submissions across cancer types, starting with CDx label in bladder cancer This module, submitted on September 28, included the required documentation regarding Natera’s ...
Sacramento Bee

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)

Company on Track to File the 5 th and Final Module in Q4 2024 IRVINE, CA / ACCESSWIRE / August 14, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new ...
TipRanks on MSN

Alpha Tau files first FDA PMA module for Alpha DaRT skin cancer therapy

An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 5, 2026, Alpha Tau Medical announced it has submitted the first ...
Charlotte Observer

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)

VenoValve PMA Approval Application Process Consists of the Submission of 5 Modules to the FDA 4 Modules Have Now Been Submitted, Reviewed, and Approved by the FDA Company on Track to File the 5 th and ...
Business Wire

Natera Submits First PMA Module to the FDA for Signatera™

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the submission of the first module of its premarket approval (PMA) application to ...